Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.

Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, Kaneko Y, Maeshima A, Kuroiwa T, Nojima Y.

Mod Rheumatol. 2014 Jul;24(4):618-25. doi: 10.3109/14397595.2013.844397. Epub 2013 Oct 21.

PMID:
24252014
2.

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.

Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL.

Ann Rheum Dis. 2016 Jan;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456. Epub 2014 Dec 30.

3.

Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.

Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, Tang CS, Chan TM.

Nephrology (Carlton). 2012 May;17(4):352-7. doi: 10.1111/j.1440-1797.2012.01574.x.

PMID:
22295934
4.

Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.

Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N.

Nephrol Dial Transplant. 2012 Apr;27(4):1467-72. doi: 10.1093/ndt/gfr484. Epub 2011 Sep 13.

PMID:
21917733
5.

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.

Lanata CM, Mahmood T, Fine DM, Petri M.

Lupus. 2010 Jul;19(8):935-40. doi: 10.1177/0961203310365714. Epub 2010 Apr 13.

PMID:
20388722
6.

Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study.

Mok CC, To CH, Yu KL, Ho LY.

Lupus. 2013 Oct;22(11):1135-41. doi: 10.1177/0961203313502864. Epub 2013 Aug 30.

PMID:
23995863
7.

Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.

Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M.

Ann Intern Med. 2015 Jan 6;162(1):18-26. doi: 10.7326/M14-1030.

PMID:
25383558
8.

Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases.

Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J.

Nephrol Dial Transplant. 2010 Dec;25(12):3939-48. doi: 10.1093/ndt/gfq322. Epub 2010 Jun 10.

PMID:
20538787
9.

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.

F L, Y T, X P, L W, H W, Z S, H Z, Z H; MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group.

Lupus. 2008 Jul;17(7):622-9. doi: 10.1177/0961203308089428.

PMID:
18625634
10.

Long-term data on tacrolimus treatment in lupus nephritis.

Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM.

Rheumatology (Oxford). 2014 Dec;53(12):2232-7. doi: 10.1093/rheumatology/keu265. Epub 2014 Jul 4.

PMID:
24996908
11.

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L.

Ann Rheum Dis. 2013 Aug;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844. Epub 2013 Jun 5.

PMID:
23740227
12.

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN.

N Engl J Med. 2000 Oct 19;343(16):1156-62.

13.

Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis.

Takahashi S, Hiromura K, Sakurai N, Matsumoto T, Ikeuchi H, Maeshima A, Kaneko Y, Kuroiwa T, Nojima Y.

Mod Rheumatol. 2011 Jun;21(3):282-9. doi: 10.1007/s10165-010-0398-z. Epub 2010 Dec 29.

PMID:
21188448
14.

Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan.

Yasuda S, Atsumi T, Shimamura S, Ono K, Hiromura K, Sada K, Mori M, Takei S, Kawaguchi Y, Tamura N, Takasaki Y.

Mod Rheumatol. 2015;25(6):854-7. doi: 10.3109/14397595.2015.1031444. Epub 2015 Apr 30.

PMID:
25800636
15.

Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis.

Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, Yamaguchi K, Okada M.

Lupus. 2012 Nov;21(13):1444-9. doi: 10.1177/0961203312458468. Epub 2012 Aug 23.

PMID:
22917589
16.

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group.

Ann Rheum Dis. 2010 Dec;69(12):2083-9. doi: 10.1136/ard.2010.131995. Epub 2010 Sep 10.

17.

Mycophenolate mofetil for remission induction in severe lupus nephritis.

Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O'Donoghue D, Jayne D; Renal Association Clinical Trials Subcommittee.

Nephron Clin Pract. 2005;100(3):c92-100. Epub 2005 Apr 11.

PMID:
15824513
19.

Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.

Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED.

J Rheumatol. 2014 Oct;41(10):1998-2007. doi: 10.3899/jrheum.140050. Epub 2014 Sep 15. Review.

PMID:
25225281
20.

Supplemental Content

Support Center